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Abstract 
Patients with recurrent IVF failure are generally regarded as having a poor prognosis, and when female 
age exceeds 35yrs such patients face a particularly bleak outlook. This study reported on blastocyst 
transfer (BT) performed over a five-year interval in patients seeking “second opinion” after multiple 
failed IVF cycles. Clinical features and reproductive outcomes were compared between two sets of poor-
prognosis IVF patients undergoing BT for the first time, the initial group underwent treatment in 2002 
(n=66) and a second group presented five years later (n=392). The two clinical sets had no patients in 
common.  The 2002 group had an average of 3.5(±1.1) prior failed IVF cycles at baseline, and mean 
(±SD) patient age was 36.4(±3.9)yrs. Average number of oocytes retrieved in this group was 
10.4(±5.3) with a fertilisation rate of 58.8%. Although embryo arrest resulted in no transfer for 19 
patients (28.8%), clinical pregnancy was achieved for 59.6% of transfers. Five years later, 392 patients 
underwent BT, but this group had an average of 4.5(±2.3) prior failed IVF cycles. Mean (±SD) female 
age was 36.0(±3.9)yrs, and the average number of oocytes retrieved in this group was 9.1(±5.4); the 
fertilisation rate was 59.5%. No blastocysts were available for transfer in 99 cases (25.3%); clinical 
pregnancy was achieved for 50.0% of transfers. The number of blastocysts transferred was similar in the 
two groups (1.6 vs. 1.3; p=0.06); the twinning rate rose slightly from 8.2% to 15.1% (p=0.12) despite 
an increased utilisation of single embryo transfer in 2007 (19.7% vs. 22.2%; p=0.40). Comparisons 
from 2002 and 2007 found no important differences between the two patient groups, except for a 
significantly higher rate of prior failed cycles in the 2007 group (p<0.001). This refractoriness was 
accompanied by a somewhat reduced blastocyst cryopreservation rate in 2007, compared to 2002 
(27.6% vs. 29.5%; p=0.44). Clinical pregnancy rates are not adversely affected by application of BT in 
patients with multiple prior unsuccessful IVF cycles. For these patients, our data suggest that extended 
embryo culture and BT should be considered. Further controlled studies are needed to document more 
precisely the role of BT in this sub-set of refractory IVF patients.  
Introduction 
Extended in vitro embryo culture and blastocyst transfer (BT) are now established components of the 
advanced reproductive technologies, permitting selection of more advanced embryos considered best 
suited for transfer. In the years since the first successful IVF, the optimal time to perform embryo 
transfer (ET) has remained a mystery. Historically, cleavage stage (day 2 or 3) ET was used first in IVF 
and therefore became established as the usual laboratory approach. This intentional placement of a day 
2 or 3 embryo directly into the uterine cavity was recognised as non-physiologic, but it was not 
immediately possible to culture such embryos until they reached the blastocyst stage for transfer. 
Accordingly, the traditional “choice” to perform day 2 or 3 ET represented a practical default in response 
to substantial technical limitations associated with extended in vitro culture. However, with the advent of 
more sophisticated sequential media, the potential for BT became a reality. Although the benefits of BT 
have been widely debated1-3, the reality of clinical practice is that not all patients are proper candidates 
for BT since it is possible that after five days in culture, no embryo will develop into a blastocyst 
resulting in cancellation of the IVF cycle. Selection criteria for BT are quite variable and there is no 
consensus on the appropriateness of BT protocols applied specifically to patients with multiple 
unsuccessful IVF cycles. Accordingly, we sought to investigate the impact of increased refractoriness to 
IVF on reproductive outcome following BT in two patient groups with a history of repetitive failed day 
three embryo transfers. 
Methods 
Patient selection and pre-treatment counselling 
All study patients initiated IVF cycles either in 2002 or 2007 (but not both); each patient had ≥2 prior 
treatment cycles utilising day 3 ET resulting either in miscarriage or no pregnancy, similar to criteria 
described previously4. A pilot BT programme was developed at our institution in 2002 reserved for 
patients referred for multiple treatment failure. The second study group underwent BT in 2007 using the 
same inclusion criteria. Written informed consent was obtained and a review of all medical records 
including laboratory data and embryology worksheets was performed before treatment commenced. A 
focused physical examination and saline infusion sonogram to assess endometrial contours were 
completed, and controlled ovarian hyperstimulation regimens were developed from factors including 
historical response to medications, patient age, BMI and ovarian reserve assessment. At entry, couples 
were counselled about outcomes and likelihood of IVF failure. From this, they expressed an 
understanding of the role of BT as a step along their fertility journey which might ultimately include 
donor oocyte IVF, or perhaps to cease fertility treatments altogether. Formal psychological counselling 
resources were offered to all couples. 
  
Controlled ovarian hyperstimulation 
Pituitary downregulation was achieved with oral contraceptives and GnRH agonist, followed by daily 
administration of gonadotropins using a combined FSH+hMG protocol. Dosing levels varied and were 
based on prior response to gonadotropins; titration was influenced by real-time assessment of follicular 
development as judged by transvaginal sonogram and/or serum oestradiol data. Treatment continued 
until adequate ovarian response was attained, defined as the maximum potential number of follicles with 
mean diameter =17mm. Transvaginal sonogram-guided oocyte retrieval was accomplished 36h after 
subcutaneous administration of hCG. 
 
Blastocyst culture protocol 
Immediately after retrieval oocyte-cumulus complexes were placed into Universal IVF medium 
(MediCult; Jyllinge, Denmark), with insemination (including ICSI) also carried out using this reagent 
under washed liquid paraffin oil (MediCult, Denmark). Fertilisation was assessed after 16-18h and was 
considered normal when two distinct pronuclei were noted. Culture was maintained to day five in 
microdrops of BlastAssist media I and II (MediCult, Denmark) under washed paraffin oil in a 5%CO2 + 
5%O2 atmosphere at 95% humidity. Embryos were assessed daily for cell number, degree of 
fragmentation, and compaction. Day five blastocysts selected for in utero transfer generally 
demonstrated a well-defined inner cell mass and highly cellular, expanding trophoectoderm. Blastocysts 
were then loaded into an embryo transfer catheter (K-Soft-5000 Catheter; Cook Medical Inc., Spencer, 
Indiana USA). All transfers occurred no earlier than 120h post-fertilisation and were uniformly carried 
out under direct transabdominal sonogram guidance by a physician. 
 
Measured parameters and statistical analysis 
The following factors were recorded and compared between the 2002 and 2007 BT groups: 1) patient 
age, 2) number of failed prior IVF (d3 ET) cycles, 3) total number of oocytes retrieved, 4) method of 
fertilisation [i.e., ICSI vs. conventional insemination], 5) fertilisation rate (%2pn), 6) frequency of cycle 
cancellation due to non-availability of blastocysts, 7) number of blastocysts transferred, 8) application of 
single blastocyst transfer, 9) clinical pregnancy (including frequency of multiple gestation outcomes). 
Due to some variation in gonadotropin formulation across patients during the five-year assessment 
period, and since not all patients had regular intracycle serum oestradiol measurements, these 
parameters were not separately studied. Student’s t-test was used for analysis, as appropriate. 
Differences measured at p<0.05 were considered significant. 
 
 
Results 
In the initial group of BT patients (n=66) treated in 2002, an average of 3.5 prior failed cycles per 
patient at baseline was reported. Mean age was 36.4yrs in this group. Although the mean patient age 
remained similar between the 2002 and the 2007 groups (p=0.13), the average number of failed IVF 
cycles/patient reported at baseline was significantly different (3.5 in 2002 vs. 4.5 in 2007; p<0.001). 
The mean number of oocytes retrieved was also lower in 2007 compared to 2002, but this decrease did 
not reach statistical significance (p=0.10). For 2002 and 2007, the proportion of IVF cycles incorporating 
intracytoplasmic sperm injection (ICSI) was almost identical, and the rate of 2pn fertilisation in these 
two groups was also similar (58.8% in 2002 vs. 59.5% in 2007; p=0.79). Comparing 2002 to 2007, 
there was a trend towards fewer IVF cycle cancellations due to cellular arrest (i.e., no blastocysts 
available) and no transfer (28.8% in 2002 vs. 25.3% in 2007), although this reduction was not 
significant (p=0.10). Mean number of embryos transferred per patient was reduced during this five year 
interval; indeed, single embryo transfer was applied more often in 2007 than in 2002, although neither 
of these changes reached statistical significance. Multiple gestation trends showed no significant change 
in the two study groups, and no monozygotic twins resulted from treatment in either group. A summary 
of clinical and laboratory features for our patients undergoing BT in 2002 and 2007 is given in Table 1. 
 
 
Discussion 
Patients not conceiving after several IVF attempts typically face a difficult prognosis, often accompanied 
by substantial emotional and financial drain. How best to guide medical decisions about recurrent IVF 
failure remains the subject of considerable debate, and is characterised by highly varied assessments 
and treatment modalities5. Diagnostic strategies generally include studies of maternal endocrine, 
anatomic, immunologic, infectious, and genetic parameters6. While oocyte quality has been regarded as 
an important element in recurrent IVF failure7, the way follicular recruitment protocols influence this 
remains difficult to measure and verify. For example, it has been proposed that adjustments to 
controlled hyperstimulation regimens in IVF might reduce embryo fragmentation and optimise gamete 
quality8. There are no controlled studies to prove this however4, and our earlier comparisons of different 
IVF stimulation regimens did not reveal any significant impact on pregnancy rate9,10.  
 
Attention has also been focused on the genetic integrity of the embryo as the extent of chromosomal 
abnormality is likely higher in embryos from patients experiencing multiple IVF failures11. Impaired 
implantation associated with embryo aneuploidy led to implantation failure being recognised as the most 
frequent cause of unsuccessful IVF, rendering blastocyst nidation the key rate-limiting step in the 
pregnancy equation12,13. For example, when pre-implantation genetic diagnosis (PGD) was applied to 
embryos from a population of patients with recurrent IVF failure, aneuploidy was noted more frequently 
in the cycle that followed the first failure14, suggesting a reduced capacity to produce “high quality” 
embryos among patients with recurrent IVF failure15. Yet for patients undergoing IVF in Ireland, any 
practical clinical role for PGD is complicated by legal and ethical issues regarding its provision here16. 
Concerns have also been raised about the paucity of robust evidence supporting a beneficial effect of 
embryo biopsy in the setting of multiple IVF failures17. It was against this background that BT has 
become positioned as an alternative to human embryo biopsy and PGD, potentially serving a helpful role 
in the management of recurrent IVF failure18. However, the impact of increased IVF refractoriness on the 
rationale to maintain BT in the treatment armamentarium for such patients remains poorly defined. 
 
To answer this, we gathered data from the first clinical blastocyst programme developed in Ireland to 
identify two populations that were fairly homogenous, except for the number of failed IVF cycles at 
baseline (before BT treatment here). Data from this institution was collected from 2002 and 2007 to 
accomplish this. None of these patients had ever had BT before, although they had all undergone 
multiple (failed) IVF cycles incorporating d3 ET. While the average patient age remained fairly 
consistent, those in the 2007 series did have significantly more prior failed IVF cycles at baseline, 
compared to the 2002 group (3.5 in 2002 vs. 4.5 in 2007; p<0.001). We also noted a trend that fewer 
oocytes were retrieved per patient in 2007 compared to 2002, accompanied by an impairment in 
blastocyst cryopreservation during this same interval (29.5% vs. 27.6%; p=0.44). Nevertheless, these 
refractory tendencies in the 2007 group did not have a significantly negative impact on overall 
reproductive outcome. Several factors could explain these findings. For example, it may be that 
expertise with blastocyst reagents and/or transfer techniques improved over time, and this adaptation 
contributed to the nearly six-fold jump in BT observed between 2002 and 2007. Interestingly, this was 
achieved with fewer embryos being transferred per patient, on average, from 2002 to 2007. While not a 
statistically important reduction, the lower embryo transfer/patient numbers in 2007 might also reflect 
enhancements of embryo culture and represents a subject of further investigation. This is a relevant 
arena for research, particularly since the multiple gestation rate trended upward (8.2% vs. 15.1%; 
p=0.12) despite enhanced utilisation of single blastocyst transfer in 2007. 
 
Concerns have recently emerged regarding a potential association between extended embryo culture 
(i.e., longer exposure to laboratory reagents) and imprinting or epigenetic mutations in offspring 
conceived after blastocyst culture and transfer19. While the mechanism(s) by which a particular culture 
milieu may affect such mutations remains unknown, we agree with the most current ASRM report on 
extended culture in IVF20 supporting standardisation of laboratory conditions and monitoring the health 
of infants conceived from this technology. Some limitations in this descriptive report must be 
acknowledged. Our sample was self-selected and confined only to BT patients; it did not include a 
matched control group undergoing d3 ET. Although d3 ET was offered to simplify treatment and to 
reduce cost, randomisation was not possible because these patients all declined another d3 ET (perhaps 
because d3 ET was identified with the earlier IVF failures). Moreover, it is not known what proportion of 
these patients might have conceived if they had undergone another d3 ET. Additionally, since our IVF 
centre is independent from a maternity hospital, collecting delivery data is a function of voluntary 
reporting from obstetricians and/or patients remote from our unit, making this information difficult to 
gather systematically. 
 
In conclusion, this report validates a role for BT for patients with multiple failed IVF cycles where d3 ET 
had been performed previously. A truly comparative investigation of d3 ET vs. BT in similar patients 
(where all other conditions are controlled), while ideal, is difficult to construct. It will be important to 
undertake further research in our population to better define which patients are best suited for BT, and 
this represents the focus of ongoing studies. 
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